Pan-TGF-β antibody fresolimumab (GC1008) has been in phase II trial for resistant idiopathic focal segmental glomerulosclerosis [162], and phase I trial in idiopathic pulmonary fibrosis (ClinicalTrials.gov Identifier: NCT00125385) and systemic sclerosis [163]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.